Oncolytic Immunotherapy Using Recombinant Vaccinia Virus GLV-1h68 Efficiently Kills Sorafenib-Resistant Hepatocellular Carcinoma

BACKGROUND: Sorafenib is the standard systemic therapy for un-resectable or recurrent hepatocellular carcinoma (HCC) with minimal increase in survival. Therefore, there is a great need to develop novel therapies for advanced or recurrent HCC. One emerging field of cancer treatment involves oncolytic...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Ady, Justin W., Heffner, Jacqueline, Mojica, Kelly, Johnsen, Clark, Belin, Laurence J., Love, Damon, Pugalenthi, Amudhan, Klein, Elizabeth, Chen, Nanhai G., Yu, Yong A., Szalay, Aladar A., Fong, Yuman
Formato: Artigo
Idioma:Inglês
Publicado: 2014
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4216725/
https://ncbi.nlm.nih.gov/pubmed/24957667
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.surg.2014.03.031
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares